Report questions use of arsenic compound for leukaemia
BMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7307.252/d (Published 04 August 2001) Cite this as: BMJ 2001;323:252- Scott Gottlieb
- New York
A new report has raised questions about the safety of arsenic trioxide, a compound recently approved in the United States for treating acute promyelocytic leukaemia, a rare subtype of acute myelogenous leukaemia.
In a study of 10 patients who had leukaemia that had relapsed or had not responded to conventional treatment and who were taking arsenic trioxide, three died suddenly, researchers reported (Blood 2001;98:266-71).
Even though the compound may provide benefits to some patients with leukaemia, “arsenic trioxide may be significantly, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.